Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-02-2030CALL0 00TRUE00
2026-02-2040CALL0 00TRUE00
2026-02-2050CALL0 00TRUE00
2026-02-2060CALL0 00TRUE00
2026-02-2070CALL0 00TRUE00
2026-02-2080CALL0 00TRUE00
2026-02-2090CALL0 00TRUE00
2026-02-20100CALL0 00TRUE00
2026-02-20110CALL0 00TRUE00
2026-02-20120CALL0 00TRUE00
2026-02-20130CALL0 00TRUE00
2026-02-20140CALL0 00TRUE00
2026-02-20152.3CALL0 00TRUE00
2026-02-20162.5CALL0 1117.1TRUE00
2026-02-20170.5CALL0 41394.9TRUE00
2026-02-20180.8CALL8 3667.06FALSE0.80
2026-02-20190.05CALL0 40177.6FALSE00
2026-02-20200.3CALL0 337172.25FALSE00
2026-02-20210CALL0 0512.06FALSE00
2026-02-20220.1CALL0 11534.67FALSE00
2026-02-20230.5CALL0 6495.87FALSE00
2026-02-20240.6CALL2 18186.02FALSE0.60
2026-02-20250CALL0 0575.85FALSE00
2026-02-20260CALL0 0609.74FALSE00
2026-02-20270CALL0 0625.61FALSE00
2026-02-20280CALL0 0640.58FALSE00
2026-02-20290CALL0 0654.75FALSE00
2026-02-20300CALL0 0668.19FALSE00
2026-02-20310CALL0 0680.98FALSE00
2026-02-20320CALL0 0693.17FALSE00
2026-02-20330CALL0 0704.81FALSE00
2026-02-20350CALL0 0676.11FALSE00
2026-02-2030PUT0 00FALSE00
2026-02-2040PUT0 00FALSE00
2026-02-2050PUT0 00FALSE00
2026-02-2060PUT0 00FALSE00
2026-02-2070PUT0 00FALSE00
2026-02-2080PUT0 01364.33FALSE00
2026-02-2090PUT0 01191.45FALSE00
2026-02-20100PUT0 01055.09FALSE00
2026-02-20110PUT0 0942.1FALSE00
2026-02-20120PUT0 0845.24FALSE00
2026-02-20130PUT0 0686.29FALSE00
2026-02-20140.2PUT0 450683.67FALSE00
2026-02-20150.1PUT20 31083.84FALSE0.10
2026-02-20160.7PUT0 434317FALSE00
2026-02-20170.39PUT410 45168.76FALSE0.390
2026-02-20182.43PUT0 48228.93TRUE00
2026-02-20193.1PUT0 12203.47TRUE00
2026-02-20204.1PUT0 9137.87TRUE00
2026-02-20212.1PUT0 1093.96TRUE00
2026-02-20220PUT0 0136.19TRUE00
2026-02-20230PUT0 0153.43TRUE00
2026-02-20240PUT0 0169.29TRUE00
2026-02-20255.9PUT0 1177.37TRUE00
2026-02-20260PUT0 0190.87TRUE00
2026-02-20270PUT0 0203.56TRUE00
2026-02-20280PUT0 0207.91TRUE00
2026-02-20290PUT0 0219.05TRUE00
2026-02-20300PUT0 0229.63TRUE00
2026-02-20310PUT0 0239.72TRUE00
2026-02-20320PUT0 0240.47TRUE00
2026-02-20330PUT0 0249.53TRUE00
2026-02-20350PUT0 0266.58TRUE00
2026-03-20100CALL0 00TRUE00
2026-03-20110CALL0 00TRUE00
2026-03-20120CALL0 00TRUE00
2026-03-20130CALL0 069.78TRUE00
2026-03-20140CALL0 067.55TRUE00
2026-03-20150CALL0 074.93TRUE00
2026-03-20160CALL0 084.88TRUE00
2026-03-20170CALL0 097.49TRUE00
2026-03-20181.35CALL0 135105.19FALSE00
2026-03-20190CALL0 0126.97FALSE00
2026-03-20201.1CALL400 078.68FALSE1.10
2026-03-20211.15CALL0 5261.95FALSE00
2026-03-20220CALL0 0273.58FALSE00
2026-03-20230CALL0 0284.29FALSE00
2026-03-20240CALL0 0294.23FALSE00
2026-03-20250.6CALL0 180303.49FALSE00
2026-03-20300CALL0 0342.19FALSE00
2026-03-20350CALL0 0372.22FALSE00
2026-03-20100PUT0 0542.8FALSE00
2026-03-20110PUT0 0484.74FALSE00
2026-03-20120PUT0 0427.94FALSE00
2026-03-20130PUT0 0391.24FALSE00
2026-03-20140PUT0 0352.01FALSE00
2026-03-20150PUT0 0316.21FALSE00
2026-03-20161.57PUT0 161170.94FALSE00
2026-03-20172PUT0 12136.59FALSE00
2026-03-20182.5PUT0 184118.57TRUE00
2026-03-20193PUT0 11101.31TRUE00
2026-03-20203.8PUT0 196.77TRUE00
2026-03-20210PUT0 0105.28TRUE00
2026-03-20220PUT0 088.15TRUE00
2026-03-20230PUT0 0108.06TRUE00
2026-03-20240PUT0 0114.71TRUE00
2026-03-20250PUT0 0103.56TRUE00
2026-03-20300PUT0 0113.36TRUE00
2026-03-20350PUT0 0155.05TRUE00
2026-04-1730CALL0 00TRUE00
2026-04-1740CALL0 00TRUE00
2026-04-1750CALL0 00TRUE00
2026-04-1760CALL0 00TRUE00
2026-04-1770CALL0 00TRUE00
2026-04-17810.3CALL0 20TRUE00
2026-04-1799.75CALL0 40TRUE00
2026-04-17105.8CALL0 2080TRUE00
2026-04-17110CALL0 00TRUE00
2026-04-17125.62CALL0 252152.99TRUE00
2026-04-17135.1CALL0 1964.01TRUE00
2026-04-17143.6CALL0 82262.3TRUE00
2026-04-17155.17CALL0 5869.36TRUE00
2026-04-17164CALL0 35576.77TRUE00
2026-04-17172.36CALL0 32373.11TRUE00
2026-04-17181.9CALL0 61685.75FALSE00
2026-04-17192.5CALL0 66195.68FALSE00
2026-04-17201.5CALL0 1425107.9FALSE00
2026-04-17211.25CALL3 255173.84FALSE0.350.39
2026-04-17250.6CALL2 439577.51FALSE0.60
2026-04-17300.24CALL0 462118.5FALSE00
2026-04-17350.2CALL0 1058282.02FALSE00
2026-04-1730PUT0 00FALSE00
2026-04-1740PUT0 00FALSE00
2026-04-1750PUT0 00FALSE00
2026-04-1760PUT0 0780.29FALSE00
2026-04-1770PUT0 0588.39FALSE00
2026-04-1780PUT0 0534.02FALSE00
2026-04-1790PUT0 0466.34FALSE00
2026-04-17101.7PUT0 0413.03FALSE00
2026-04-17111.85PUT0 13368.89FALSE00
2026-04-17120.75PUT0 14331.09FALSE00
2026-04-17130.8PUT0 55297.87FALSE00
2026-04-17143.2PUT0 11268.07FALSE00
2026-04-17151.55PUT0 133240.89FALSE00
2026-04-17161.5PUT0 6119.35FALSE00
2026-04-17172.3PUT0 1107.92FALSE00
2026-04-17181.8PUT0 13189.13TRUE00
2026-04-17193.7PUT0 3087.64TRUE00
2026-04-17204.1PUT0 2184.4TRUE00
2026-04-17210PUT0 091.16TRUE00
2026-04-17257.6PUT0 293.18TRUE00
2026-04-173010.2PUT0 3100.99TRUE00
2026-04-17350PUT0 0117.82TRUE00
2026-07-1730CALL0 00TRUE00
2026-07-1740CALL0 00TRUE00
2026-07-1750CALL0 00TRUE00
2026-07-1760CALL0 00TRUE00
2026-07-1770CALL0 00TRUE00
2026-07-1780CALL0 00TRUE00
2026-07-1790CALL0 066.45TRUE00
2026-07-17109.2CALL0 2061.12TRUE00
2026-07-17110CALL0 055.54TRUE00
2026-07-17127.9CALL0 1179TRUE00
2026-07-17136.9CALL0 359.05TRUE00
2026-07-17146.3CALL0 460.94TRUE00
2026-07-17155.61CALL0 961.95TRUE00
2026-07-17163.52CALL0 2168.57TRUE00
2026-07-17173.2CALL0 54266.13TRUE00
2026-07-17183CALL2 761.67FALSE0.250.09
2026-07-17192.05CALL0 1667.07FALSE00
2026-07-17201.8CALL0 6271.34FALSE00
2026-07-17212.85CALL0 5251.7FALSE00
2026-07-17222.75CALL0 102133.14FALSE00
2026-07-17233.1CALL0 5138.46FALSE00
2026-07-17243CALL0 1143.39FALSE00
2026-07-17251CALL0 1723147.98FALSE00
2026-07-17300CALL0 0167.16FALSE00
2026-07-17350CALL0 0182.01FALSE00
2026-07-1730PUT0 00FALSE00
2026-07-1740PUT0 00FALSE00
2026-07-1750PUT0 00FALSE00
2026-07-1760PUT0 0511.69FALSE00
2026-07-1770PUT0 0410.47FALSE00
2026-07-1780PUT0 0349.25FALSE00
2026-07-1790PUT0 0304.98FALSE00
2026-07-17100PUT0 0270.18FALSE00
2026-07-17111.5PUT0 5241.41FALSE00
2026-07-17120PUT0 0216.78FALSE00
2026-07-17130PUT0 0195.17FALSE00
2026-07-17142.2PUT0 1175.8FALSE00
2026-07-17152.65PUT0 1158.14FALSE00
2026-07-17162.3PUT3 875.26FALSE2.30
2026-07-17173.8PUT0 2165.28FALSE00
2026-07-17180PUT0 049.66TRUE00
2026-07-17194.1PUT0 149.06TRUE00
2026-07-17200PUT0 066.37TRUE00
2026-07-17210PUT0 075.31TRUE00
2026-07-17220PUT0 073.92TRUE00
2026-07-17230PUT0 077.29TRUE00
2026-07-17240PUT0 075.71TRUE00
2026-07-17250PUT0 080.38TRUE00
2026-07-17300PUT0 082.09TRUE00
2026-07-17350PUT0 095.09TRUE00
2027-01-1530CALL0 00TRUE00
2027-01-1550CALL0 00TRUE00
2027-01-1588.5CALL0 262.23TRUE00
2027-01-15106.9CALL0 26665.09TRUE00
2027-01-15128.74CALL0 1073.45TRUE00
2027-01-15130CALL0 00TRUE00
2027-01-15155.5CALL0 2774.67TRUE00
2027-01-15176.5CALL0 44972.27TRUE00
2027-01-15203.57CALL0 32662.17FALSE00
2027-01-15223.5CALL0 8374.44FALSE00
2027-01-15252.9CALL0 7370.35FALSE00
2027-01-15273.21CALL0 495105.12FALSE00
2027-01-15302.75CALL0 52112.56FALSE00
2027-01-15350CALL0 0122.75FALSE00
2027-01-1530PUT0 00FALSE00
2027-01-1550PUT0 00FALSE00
2027-01-1580PUT0 0241.54FALSE00
2027-01-15102.45PUT0 52171.76FALSE00
2027-01-15120PUT0 0150.23FALSE00
2027-01-15130PUT0 00FALSE00
2027-01-15153PUT0 173.67FALSE00
2027-01-15170PUT0 072.16FALSE00
2027-01-15207.75PUT0 5374.13TRUE00
2027-01-15220PUT0 075.84TRUE00
2027-01-15250PUT0 072.44TRUE00
2027-01-15270PUT0 078.71TRUE00
2027-01-15300PUT0 071.49TRUE00
2027-01-15350PUT0 073.87TRUE00
2028-01-2130CALL0 00TRUE00
2028-01-2150CALL0 061.79TRUE00
2028-01-21811.51CALL0 268.22TRUE00
2028-01-21109.1CALL0 1661.7TRUE00
2028-01-21128.2CALL0 263.29TRUE00
2028-01-21157.7CALL2 2264.08TRUE0.90.13
2028-01-21177.1CALL102 121665.96TRUE0.90.15
2028-01-21206.2CALL445 193266.51FALSE0.70.13
2028-01-21225.8CALL406 103667.98FALSE0.80.16
2028-01-21255.1CALL218 34467.9FALSE0.70.16
2028-01-21274.6CALL249 105366.91FALSE0.40.1
2028-01-21304.3CALL1084 65569.17FALSE4.30
2028-01-21353.7CALL1133 94270.33FALSE0.60.19
2028-01-2130PUT0 00FALSE00
2028-01-2150PUT0 00FALSE00
2028-01-2180PUT0 0171.93FALSE00
2028-01-21102.07PUT36 7074.8FALSE2.070
2028-01-21123.22PUT2 3278.01FALSE3.220
2028-01-21154.75PUT10 3075.92FALSE-0.25-0.05
2028-01-21170PUT0 078.59FALSE00
2028-01-21209PUT0 1076.17TRUE00
2028-01-212211PUT0 1077.08TRUE00
2028-01-212512.5PUT0 3074.67TRUE00
2028-01-21270PUT0 074.23TRUE00
2028-01-21300PUT0 075.36TRUE00
2028-01-21350PUT0 073.65TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm